source
- AI drug developer Pathos secures $237 million Series E, valuation hits $3 billionPathos announced a $237 million Series E round led by Bristol Myers Squibb, lifting its valuation to about $3 billion. The funding will support expansion beyond oncology into neurology, leveraging…
- Warp Sciences raises $215 million Series A to apply AI in drug building-block designFormer OpenAI head of science Kevin Weil announced the launch of Warp Sciences, a new startup aimed at accelerating the creation of molecular building blocks for drug discovery. The company secure…